Search

Your search keyword '"Cacho, Diego"' showing total 13 results
Start Over Author "Cacho, Diego"
13 results on '"Cacho, Diego"'

1. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

Author

García-Donas, Jesús, de Velasco, Guillermo, Madurga, Rodrigo, Chamorro, Jesús, Rosero, Diana, Etxaniz, Olatz, Pérez-Gracia, Jose Luis, Pinto, Álvaro, Cacho, Diego, Barba, María, Borrega, Pablo, Lázaro, Martín, Rodriguez, Laura, Villalobos, Laura, García, Lourdes, Cuellar, Andrés, Solís-Hernández, María Pilar, González, Amalia, Pernaut, Cristina, and Rodríguez-Moreno, Juan Francisco

Published
2024
Full Text
View/download PDF

5. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

Author

García-Donas, Jesús, primary, de Velasco, Guillermo, additional, Madurga, Rodrigo, additional, Chamorro, Jesús, additional, Rosero, Diana, additional, Etxaniz, Olatz, additional, Pérez-Gracia, Jose Luis, additional, Pinto, Álvaro, additional, Cacho, Diego, additional, Barba, María, additional, Borrega, Pablo, additional, Lázaro, Martín, additional, Rodriguez, Laura, additional, Villalobos, Laura, additional, García, Lourdes, additional, Cuellar, Andrés, additional, Solís-Hernández, María Pilar, additional, González, Amalia, additional, Pernaut, Cristina, additional, and Rodríguez-Moreno, Juan Francisco, additional

Published
2023
Full Text
View/download PDF

7. The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC).

Author

Caramelo, Belen, Muñoz Unceta, Nerea, Freire, Javier, Varela, Ignacio, Martin, David, Del Carmen, Sofía, Azueta, Ainara, Diaz, Pilar, Garcia-Berbel, Pilar, Sagastibelza Marinelarena, Naiara, Rey-Cárdenas, Macarena, Castellano, Daniel, Climent, Miguel Ángel, Puente, Javier, Irure, Juan, Revuelta, Laura, Genre, Fernanda, Cacho, Diego, Gómez, Javier, and Duran, Ignacio

Published
2024
Full Text
View/download PDF

9. Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.

Author

Serrano, Marina, Muñoz-Unceta, Nerea, Alonso, Lucía Andrea, Azueta, Ainara, Gutiérrez Baños, José Luis, Ferreira, Laura, Domínguez, Mario, Torres Zurita, Albero, Ballestero, Roberto, Cacho, Diego, López-Brea, Marta, Sotelo, Marta, Campos-Juanatey, Félix, Ramos Barseló, Enrique, and Duran, Ignacio

Abstract

Purpose: Neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) patients has proven beneficial in overall survival. However, the optimal regimen is still a matter of debate. Materials and methods: In this retrospective analysis, we evaluate the results obtained in 42 patients treated in our center with 4 cycles of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) followed by radical cystectomy from August 2015 to October 2020. All patients had cT2 or higher non-metastatic MIBC. Clinical and pathological outcomes are reported. Results: Of the 42 patients, 90.5% were men (n = 38) and the mean age was 65 years. All of them had ECOG 0–1 at diagnosis and most tumors had an initial clinical stage T2N0 (76%). Thirty-six patients (85.7%) completed 4 cycles of neoadjuvant treatment, and 21.4% required a dose reduction. The most frequent adverse event (AE) was grade 1–2 asthenia (81%), while neutropenia was the most frequent grade 3 or higher AE (38%). Complete pathological response (ypT0, ypN0) was achieved in 50% of patients (n = 21), and down-staging was observed in 57.1% (n = 24). Only one patient presented radiological progressive disease during neoadjuvant treatment (2.4%), and after a mean follow-up time of 31.5 months, 33.3% of patients experienced disease recurrence. Conclusions: Neoadjuvant chemotherapy with 4 cycles of dd-MVAC is an effective regimen with high rates of pathological complete responses and down-staging along with an acceptable toxicity profile. DD-MVAC should be considered as an alternative to cisplatin and gemcitabine in patients with good clinical performance status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.

Author

Donas, Jesus Garcia, primary, de Velasco, Guillermo, additional, Alonso Gordoa, Teresa, additional, Chamorro, Jesús, additional, Rosero, Diana, additional, Etxaniz, Olatz, additional, Perez-Gracia, Jose Luis, additional, Pinto, Alvaro, additional, Duran, Ignacio, additional, Cacho, Diego, additional, Barba, María, additional, Yagüe, Monica, additional, Borrega, Pablo, additional, Lázaro, Martín, additional, Rodriguez, Laura, additional, Villalobos Leon, Maria Laura L., additional, Garcia Sanchez, Lourdes, additional, Cuellar, M. Andres, additional, and Rodriguez-Moreno, Juan Francisco, additional

Published
2021
Full Text
View/download PDF

12. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

Author

Zugazagoitia, Jon, primary, Biosca, Mercedes, additional, Oliveira, Julio, additional, Olmedo, María Eugenia, additional, Dómine, Manuel, additional, Nadal, Ernest, additional, Ruffinelli, José Carlos, additional, Muñoz, Nerea, additional, Luna, Ana María, additional, Hernández, Berta, additional, Martínez, Maite, additional, Gallego, Iria, additional, Martínez de Castro, Eva, additional, Font, Carme, additional, Calvo, Virginia, additional, Martínez-Marín, Virginia, additional, Corral, Jesús, additional, Noguerón, Esther, additional, Mondéjar, Rebeca, additional, García Escobar, Ignacio, additional, Salvador-Coloma, Carmen, additional, Juan, Óscar, additional, Sánchez Cánovas, Manuel, additional, Valdivia, Javier, additional, Ochoa, M. Pilar, additional, López Castro, Rafael, additional, Obispo, Berta, additional, Pangua, Cristina, additional, Sereno, María, additional, Fernández Franco, Lourdes, additional, Mielgo, Xabier, additional, Calzas, Julia, additional, Blasco, Ana, additional, Aparisi, Francisco, additional, Chara, Luis, additional, Grau, Juan Francisco, additional, Soares, Marta, additional, Gómez, Ana, additional, Zenzola, Victor, additional, García-Morillo, Marcial, additional, Cacho, Diego, additional, Díaz-Serrano, Asunción, additional, Aguado, Carlos, additional, Ponce-Aix, Santiago, additional, González-Larriba, Jose Luis, additional, Muñoz, Andrés J., additional, Lora, David, additional, Paz-Ares, Luis, additional, and Manzano, Aránzazu, additional

Published
2018
Full Text
View/download PDF

13. Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA).

Author

Pericay, Carles, primary, Martinez, Nieves Purificacion, additional, Corral, Monica, additional, Macias, Ismael, additional, Donnay, Olga, additional, Juez, Ignacio, additional, García-Paredes, Beatriz, additional, Mendez, Jose Carlos, additional, Cacho, Diego, additional, Gonzalez Astorga, Beatriz, additional, Ruiz, Ana, additional, Delgado, Mayte, additional, Rodriguez, Nuria, additional, Calderero, Veronica, additional, Mata, Elena, additional, and Barrera Ramirez, Juan Antonio, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results